Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has provided an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the composition of its board of directors and their roles within the company. This announcement outlines the executive, non-executive, and independent non-executive directors, as well as their assignments to various board committees, which are crucial for the company’s governance and strategic decision-making processes.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in China, focusing on the development of innovative cancer immunotherapies. The company is engaged in research and development activities to create novel treatments that harness the immune system to combat cancer.
Average Trading Volume: 5,194,140
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.61B
Find detailed analytics on 1541 stock on TipRanks’ Stock Analysis page.